

1 **Comparing survival in urinary tract cancer patients with**
2 **various second primary malignancies: A population-based**
3 **study**

4 **Xiang Gao^{1¶}, Hui Cao^{2¶}, Liang Zhou^{3¶}, Xiaopan Li⁴, Yongbin Zou⁵, Dehua Yu⁶, Jinsong Geng⁷, Haiyi**
5 **Jia⁸, Yipeng Lv⁹, Wenya Yu¹⁰, Yichen Chen¹¹, Zhaoxin Wang^{12*}, Jianwei Shi^{13*}, Hua Jin^{14*}**

6 1 School of Public Health, Shanghai Jiaotong University, Shanghai, China

7 2 Department of Oncology, Chenzhou First People's Hospital, Hunan, China

8 3 School of Public Health, Shanghai Jiaotong University, Shanghai, China

9 4 Center for Disease Control and Prevention, Pudong New Area, Shanghai, China; Fudan University Pudong

10 Institute of Preventive Medicine, Pudong New Area, Shanghai, China;

11 5 Department of Oncology, Chenzhou First People's Hospital, Hunan, China;

12 6 Academic Department of General Practice, School of Medicine, Tongji University, Shanghai, China;

13 Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai,

14 China; Shanghai General Practice and Community Health Development Research Center, Shanghai, China;

15 7 Medical School of Nantong University, Nantong, China;

16 8 Zhongshan Hospital of Fudan University, Shanghai, China;

17 9 School of Public Health, Shanghai Jiaotong University, Shanghai, China

18 10 School of Public Health, Shanghai Jiaotong University, Shanghai, China

19 11 Center for Disease Control and Prevention, Pudong New Area, Shanghai, China; Fudan University

20 Pudong Institute of Preventive Medicine, Pudong New Area, Shanghai, China;

21 12 School of Public Health, Shanghai Jiaotong University, Shanghai, China;

22 13 School of Public Health, Shanghai Jiaotong University, Shanghai, China;

23 14 Academic Department of General Practice, School of Medicine, Tongji University, Shanghai, China;

24 Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai,

25 China; Shanghai General Practice and Community Health Development Research Center, Shanghai, China;

26 ¶ These authors share first authorship.

27 * These authors are co-corresponding authors on this work:

28 Zhaoxin Wang: supercell002@sina.com; Jianwei Shi: shijianwei_amy@126.com;

29 Hua Jin: rjinhua@tongji.edu.cn.

30

31 Abstract

32 **Purpose:** We aimed to identify the patterns and combinations of second primary malignancies (SPMs)
33 observed in patients with malignant neoplasms of the urinary tract (MNUT) and to explore the independent
34 risk factors for survival outcomes in these patients.

35 **Materials and Methods:** We analysed the data of MNUT patients with SPM in 25 hospitals in Shanghai
36 between 2002 and 2015. A life table was used to calculate the survival rates, Kaplan–Meier analysis was
37 used to determine the survival status of MNUT patients, and Cox regression analysis was used to perform
38 multivariate analysis of survival risk factors in MNUT patients with SPM.

39 **Results:** Among the 154 patients included, the first primary malignancy (PM) most commonly occurred in
40 the bladder (50.65%) and kidney (41.56%), and the SPM most commonly occurred in the lung (22.73%) and
41 stomach (13.64%). The most common combinations included the bladder + lung and bladder + stomach. The
42 Cox regression results showed that age older than 60 years (HR = 2.36 [95% CI 1.30–4.28] vs. age ≤60 years,
43 p = 0.005), TNM 1 stage III+IV disease (HR = 2.19 [95% CI 1.37-4.57] vs. I+ II), p = 0.037), TNM 2 stage
44 III+IV disease (HR = 7.43 [95% CI 1.49-19.68] vs. I + II), p <0.001), and SPM in the lung (HR = 4.36 [95%
45 CI 1.74-18.69], p = 0.047) were associated with a significantly worse cancer-specific survival.

46 **Conclusion:** The survival of MNUT patients with SPM may be related to the SPM site, first and second PM
47 staging and latency time.

48 **Keywords:** malignant neoplasms of the urinary tract, second primary malignancy, risk factors, survival,
49 population-based study

50 **Introduction**

51 Cancer is the leading cause of death in the world. In 2020, cancer caused nearly 10 million deaths worldwide.
52 The number of new occurrences and deaths of malignant neoplasms of the urinary tract (MNUT) has
53 increased year by year, with figures for bladder and kidney neoplasms reaching 1.005 million and 392,000,
54 respectively(1). Benefiting from the great advances in diagnostic techniques and treatment methods for
55 MNUT, the survival rate of patients is gradually improving(2, 3). Studies have shown that second primary
56 malignancy (SPM) is a serious and potentially fatal long-term complication of cancer patients, which places
57 a heavier burden on the survival of patients with MNUT(4). Therefore, it is important to track and manage
58 the survivors of MNUT and research SPM.

59 Previous studies have analysed the risk and influencing factors of SPM for specific MNUTs. For
60 example, Beisland, C et al. analysed the multiple primary malignant tumours of 1,425 patients with renal cell
61 carcinoma in Norway and explored the incidence of multiple malignant tumours of renal cell carcinoma and
62 their combined pattern(5). Liu, Y et al. downloaded SPM sample data from the Surveillance, Epidemiology,
63 and End Results (SEER) database, analysed the incidence of SPM in patients with prostate cancer, and further
64 clarified the common sites of SPM and the influencing factors of survival(6). Some scholars have also
65 analysed the survival risk of specific MNUT patients with SPM. For example, Kyo Chul Koo et al. analysed
66 the incidence of SPM in prostate cancer patients and the influencing factors of survival(7). However, to the
67 best of our knowledge, current research focuses more on a specific MNUT and is limited to fewer data, and
68 the overall pattern of MNUT is not yet clear. Moreover, few studies on survival models consider the impact
69 of SPM on the survival of patients with MNUT, and it has been found that the location of malignant tumours
70 is an important prognostic factor for the survival rate of SPM patients.

71 Therefore, the purpose of this study was to first establish the SPM patterns of MNUTs overall by using
72 measurement data from 25 hospitals in Shanghai, China, and then analyse the survival of common SPM
73 categories in terms of the first MNUT and its SPM site. Finally, we assessed the factors affecting cancer
74 mortality and all-cause mortality in SPM patients.

75 **Materials and methods**

76 *Data collection*

77 The diagnosis and survival data of MNUT patients with SPM in this study were collected from 25 hospitals
78 in Shanghai. The assessment and examination of data quality was based on the China Cancer Registration
79 Guidelines and the International Agency for Research on Cancer/International Association for the
80 Registration of Cancer data quality standards. Relevant population data were provided by the Shanghai
81 Bureau of Statistics and the Public Security Bureau.

82 We analysed the data of MNUT patients with SPM from 25 hospitals in Shanghai, China, between 1 January
83 2002 and 31 December 2015. In addition, we included patients who were diagnosed with MNUT before 2002
84 but were subsequently diagnosed with SPM in 2002–2015. After patients provided informed consent, we
85 conducted annual follow-up surveys of patients through home visits or telephone calls according to standard
86 epidemiological procedures to assess the survival rate(8). The follow-up observation continued until the date
87 of death or December 31, 2017, to resolve the 3-year time lag in information collection and data quality
88 control. According to ICD-10, 5 types of urinary tract malignancies (C64-C68) were identified. After
89 screening the first primary malignancy (PM) site of the MNUT and excluding 22 patients with 3 PMs, a total
90 of 154 urinary organ cancer patients with SPM were identified as the subjects of the study (**Figure 1**).

91 *Variables*

92 The following demographical and clinical variables were used in our study: age at diagnosis (patients \leq 60
93 years and $>$ 60 years were stratified into the non-older group and older group, respectively(9)), American
94 Joint Committee on Cancer (AJCC) 7th tumour-node-metastasis (TNM) staging classification(10), year of
95 diagnosis, level of hospital, latency (the interval between the first PM diagnosis and the SPM diagnosis(11))
96 and site of SPM. TNM 1 represents the TNM staging classification of the first PM (MNUT), and TNM 2
97 represents the TNM staging classification of the SPM.

98 *Statistical analysis*

99 We used a life table to calculate the 1–5-year survival rate, Kaplan-Meier analysis to determine the survival
100 status of patients with urinary system cancer, and Cox regression analysis for multivariate analysis of survival
101 risk factors for MNUT patients with SPM. A two-sided test was used for analysis, and the statistical software
102 used was SPSS 20.0. $P < 0.05$ was considered to indicate a significant difference.

103 **Results**

104 *Population and characteristics*

105 Among the 154 MNUT patients with SPM, there were 119 male patients, accounting for 77.27%, and 35
106 female patients, accounting for 22.73%. From the perspective of age distribution, the patients were mostly
107 over 65 years, accounting for 70.78%. The proportion of patients with TNM 1 and TNM 2 in grade III+IV
108 was higher than the proportion of patients in grade I+II. Most patients were diagnosed with MNUT in tertiary
109 hospitals (76.62%) between 2002 and 2008 (66.88%). In addition, most people were diagnosed with SPM in
110 tertiary hospitals (59.09%) between 2009 and 2015 (81.82%). The latency between the first and second PM
111 diagnoses in most patients was less than 12 months (81.17%). Among the SPM sites of MNUT, lung, stomach
112 and colon were the most common, accounting for 22.73%, 13.64% and 11.69% of the total, respectively
113 (**Table 1**).

114 **Table 1 Characteristics of MNUT patients with SPM (n, %)**

Variables	Male	Female	Total
Age at SPM diagnosis			
≤60 years	32(26.89%)	13(37.14%)	45(29.22%)
>60 years	87(73.11%)	22(62.86%)	109(70.78%)
TNM 1 (MNUT) stage			
III+IV	69(57.98%)	20(57.14%)	89(57.79%)
I+II	3(2.52%)	4(11.43%)	7(4.55%)
Missing	47(39.50%)	11(31.43%)	58(37.66%)
TNM 2 (SPM) stage			

III+IV	32(26.89%)	10(28.57%)	42(27.27%)
I+II	17(14.29%)	12(34.29%)	29(18.83%)
Missing	70(58.82%)	13(37.14%)	83(53.90%)
Time of first PM (MNUT) diagnosis (year)			
2009–2015	37(31.09%)	14(40.00%)	51(33.12%)
2002–2008	82(68.91%)	21(60.00%)	103(66.88%)
Time of SPM diagnosis (year)			
2009–2015	98(82.35%)	28(80.00%)	126(81.82%)
2002–2008	21(17.65%)	7(20.00%)	28(18.18%)
Hospital level for first PM (MNUT)			
Secondary	28(23.53%)	8(22.86%)	36(23.38%)
Tertiary	91(76.47%)	27(77.14%)	118(76.62%)
Hospital level for SPM			
Secondary	51(42.86%)	12(34.29%)	63(40.91%)
Tertiary	68(57.14%)	23(65.71%)	91(59.09%)
Latency between MNUT and SPM			
≤ 12 months	98(82.35%)	27(77.14%)	125(81.17%)
> 12 months	21(17.65%)	8(22.86%)	29(18.83%)
SPM site			
Lung	29(24.37%)	6(17.14%)	35(22.73%)
Stomach	17(14.29%)	4(11.43%)	21(13.64%)
Colon	16(13.45%)	2(5.71%)	18(11.69%)
Prostate	11(9.24%)	0(0.00%)	11(7.14%)
Bladder	6(5.04%)	4(11.43%)	10(6.49%)
Others	40(33.61%)	19(54.29%)	59(38.31%)

115

116 **Figure 2** shows the distribution of first and second PMs in 154 patients with MNUT. The main sites of
 117 MNUT were the bladder (n=78, 50.65%) and kidney (n=64, 41.56%). When the first PM occurred in the
 118 bladder, the most common SPM sites were the lungs (n=19, 24.36%), stomach (n=12, 15.38%) and prostate

119 (n=9, 11.54%). When the first PM occurred in the kidney, the most common SPM sites were the lungs (n=12,
120 18.75%), colon (n=9, 14.06%), bladder (n=8, 12.50%) and stomach (n=8, 12.50%).

121 The survival rates of first and second PM patients are shown in **Table 2**. Taking the first PM site as the
122 centre, bladder cancer patients had relatively low survival rates, with 1-year, 2-year, 3-year, 4-year and 5-
123 year survival rates of 94.87%, 83.33%, 76.92%, 74.36% and 65.38%, respectively. When the SPM site was
124 the lung, the observed survival rate was the lowest. The 1-year, 2-year, 3-year, 4-year, and 5-year survival
125 rates were 54.29%, 37.14%, 22.86%, 14.29%, and 2.86%, respectively.

126 **Table 2 Survival rates of primary malignancy patients based on the MNUT and SPM site during 2002–2015**

Site	Survival rates (%)					
	N	1-year	2-year	3-year	4-year	5-year
First primary malignancy						
Bladder	78	94.87	83.33	76.92	74.36	65.38
Kidney	64	95.31	92.19	89.06	81.25	68.75
Others	12	91.67	83.33	75.00	66.67	66.67
Second primary malignancy						
Lung	35	54.29	37.14	22.86	14.29	2.86
Stomach	21	61.90	42.86	38.10	33.33	23.81
Colon	18	83.33	72.22	55.56	16.67	5.56
Prostate	11	72.73	72.73	72.73	54.55	18.18
Bladder	10	80.00	80.00	20.00	20.00	20.00
Others	59	74.58	66.10	55.93	33.90	27.12

127

128 ***Possible risk factors for the survival status of MNUT patients with SPM***

129 Kaplan-Meier analysis showed that there were significant differences in the cancer-specific survival rates of
130 patients with different age groups, TNM levels, and SPM sites ($p < 0.05$) (**Figure 3**). Specifically, patients
131 older than 60 years of age have a higher risk of cancer death than patients younger than 60 years of age.

132 Patients with TNM 2 stage III+IV disease have a higher risk of cancer death than those with TNM 2 stage
 133 I+II disease. The risk of cancer death in patients with SPM found in the lung was higher than that in patients
 134 with SPM found in the bladder and prostate. Other variables, such as sex, time of diagnosis, hospital level,
 135 and time between first and second cancers, had no statistically significant influence on cancer survival. The
 136 overall survival rate was the same as the cancer-specific survival rate. Advanced age, TNM stage III+IV
 137 disease and lung SPM site were important risk factors for all-cause death.

138 After univariate analysis, variables ($p < 0.3$) were selected for Cox regression analysis, and 4 variables
 139 were shown to be independent risk factors for cancer survival (**Table 3**). For cancer-specific survival, patients
 140 older than 60 years (compared to patients ≤ 60 years old) had a 2.36-fold increased risk of death (HR = 2.36
 141 [95% CI 1.30–4.28] vs. age ≤ 60 years, $p = 0.005$). TNM 1 III+IV patients had a 2.19-fold increase in the risk
 142 of death (HR = 2.19 [95% CI 1.37-4.57] vs. I+ II, $p = 0.037$). In addition, MNUT patients with TNM 2 stage
 143 III+IV disease (compared to patients with TNM 2 stage I+II disease) had a 7.43-fold increase in the risk of
 144 death (HR = 7.43 [95% CI 1.49-19.68] vs. I+ II), $p < 0.001$). It should also be noted that patients with urinary
 145 tract malignancies had a significantly higher risk of dying from lung SPM (HR = 4.36 [95% CI 1.74-18.69],
 146 $p = 0.047$). Unlike the cancer-specific survival rate, there was no significant difference in the effect of the
 147 site of SPM on the overall survival rate.

Table 3. Multivariate Cox regression of independent risk factors for cancer-specific and overall survival in MNUT patients with SPM

Variables	Cancer-specific survival		Overall survival	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age				
≤ 60 years	Reference		Reference	
> 60 years	2.36(1.30-4.28)	0.005	2.40(1.34-4.28)	0.003
TNM 1				
Stage I + II	Reference		Reference	
Stage III + IV	2.19(1.37-4.57)	0.037	2.43(1.20-4.94)	0.014
Missing	1.46(1.24-2.37)	0.127	1.50(1.93-2.42)	0.099
TNM 2				
Stage I + II	Reference		Reference	

Stage III + IV	7.43(1.49-19.68)	0.000	6.76(1.73-16.78)	0.000
Missing	3.67(1.47-9.33)	0.006	3.32(1.40-7.90)	0.006
SPM site				
Bladder	Reference		Reference	
Lung	4.36(1.74-18.69)	0.047	4.32(1.99-18.85)	0.051
Stomach	3.29(1.75-14.46)	0.115	3.08(1.68-13.84)	0.143
Colon	1.34(1.79-6.37)	0.712	1.27(1.26-6.27)	0.769
Prostate	1.80(1.82-9.09)	0.476	2.12(1.43-10.43)	0.357
Others	2.47(1.74-10.60)	0.224	2.95(1.68-12.74)	0.148

148

149 **Discussion**

150 MNUTs are one of the most common types of malignant neoplasms. With the increase in the incidence of
 151 SPM, an increasing number of studies have begun to pay attention to the current status and risks of SPM(12).
 152 Although some studies have discussed the death risk of SPM in patients with specific urinary tract
 153 malignancies, such as kidney and prostate malignancies, due to a lack of data, the overall pattern of SPMs in
 154 MNUT and the risk factors related to survival still need to be further analysed and discussed.

155 In this study, we found that malignant neoplasms of the kidney and bladder were the most common
 156 MNUTs with SPM in Shanghai. This result was consistent with the research results of other scholars. For
 157 example, Jae Young Joung et al. found that the risk of SPM in patients with primary kidney cancer was higher
 158 than the cancer risk in the general population(13). In addition, this study found that the most common SPM
 159 site in patients with MNUT was the lung (35, 22.73%). This was consistent with the study findings of AMIT
 160 KHANAL(14). Because smoking is a well-known risk factor for malignant neoplasms of the lung, the main
 161 risk factors for malignant neoplasms of the bladder and other MNUTs include cigarette smoke,
 162 naphthylamine, azo dyes, and long-term use of cyclophosphamide or phenacetin(15, 16). Therefore, the
 163 increased risk of lung cancer in patients with a history of MNUT may be secondary to a common cause.

164 In addition, when analysing the combination of MNUTs, we observed a certain symbiosis of MNUTs,
 165 such as bladder+prostate and kidney+bladder. A similar phenomenon was found in previous studies.
 166 Following bladder cancer, the risk of renal pelvic, bladder, and ureter malignancies is significantly

167 increased(14). This may be because the bladder, renal pelvis and ureter are lined by the same urothelium and
168 are susceptible to the same risk factors for carcinogens in urine. Kotake T et al. found that the relative risk of
169 prostate cancer was significantly increased after bladder cancer. The study analysed cases reported in the
170 Japanese literature and found that the association with urinary system cancers may be because patients are
171 highly sensitive to both cancers, or they may share similar carcinogenic processes, such as DNA repair and
172 N-acetyltransferase polymorphism(17, 18).

173 According to Kaplan-Meier curve and multivariate Cox regression analyses, we found that patients in
174 the advanced age group have a higher cancer death risk and all-cause death risk, and patients with stage III-
175 IV diseases have a higher mortality rate when they are diagnosed with a first and second PM. This is mainly
176 because patients diagnosed at a late stage cannot receive early treatment. Previous studies have suggested
177 that the survival of patients with urinary tract malignancies with SPM depends to a large extent on the cancer
178 stage at the time of diagnosis. For example, Jae Young Joung et al. found in a study that patients diagnosed
179 with advanced renal cancer have poor survival outcomes. Early cancer is associated with a more favourable
180 prognosis and a survival period of more than 10 years after complete resection(13). This means that if the
181 public is encouraged to conduct early screening to identify urinary tract malignant tumours and their SPM
182 earlier, they will be more likely to achieve good survival results.

183 Regarding the location of SPM, patients with urinary organ cancer with SPM in the lungs have a higher
184 risk of death than patients with SPM in other locations. This is consistent with the results of previous studies.
185 For example, Nicholas Donin MD and other scholars found in a study on the survival risk of cancer survivors
186 with SPM in the United States that a large proportion of cancer survivors will develop and die from lung
187 cancer(4). This result is also consistent with the known epidemiology of lung cancer. Lung cancer is still the
188 leading cause of cancer-related deaths in many countries worldwide(1, 19-21).

189 In this study, factors such as sex and the time interval between the first and second PM did not have a
190 significant effect on cancer mortality or all-cause mortality. These findings were different from those of
191 previous studies, such as the Chinese Cancer Statistics Study, which showed that male cancer patients have
192 a higher overall mortality rate(22). Of course, this conclusion needs to be confirmed by further studies with
193 a larger sample size.

194 There are several limitations to consider. First, during the follow-up period, some patients lacked
195 information on TNM staging, which led to a lack of information for these patients in the Cox regression
196 analysis. Second, the sample size of this study was limited, and MNUT can only be used as a whole to analyse
197 the impact of SPM on death. However, it is impossible to realize the analysis of risk factors for death of
198 specific MNUTs combined with SPMs. In addition, due to the sample size, this study could not analyse 4
199 patients with 3 PMs in depth.

200 **Conclusions**

201 The most common site of SPM is the lung. It is worth noting that patients with first and second PM in
202 stages III-IV have a higher risk of cancer-specific death and all-cause death. Patients with MNUT whose
203 SPM site is in the lung had a higher risk of specific and all-cause death than those with other sites of SPM.
204 Future research is necessary to confirm our findings and translate them into SPM monitoring and treatment
205 strategies to improve the prognosis of patients with MNUT after the development of SPM.

206 **Acknowledgments**

207 Conceptualization, Xiang Gao and Jianwei Shi; methodology, Zhaoxin Wang and Hua Jin; software, Hui
208 Cao and Liang Zhou; validation, Dehua Yu, and Jinsong Geng; formal analysis, Yongbin Zou, Yipeng Lv,
209 Wenya Yu and Yichen Chen; resources, Xiaopan Li and Hua Jin; data curation, Xiang Gao and Haiyi Jia;
210 writing—original draft preparation, Xiang Gao and Haiyi Jia; writing—review and editing, Xiang Gao and
211 Jianwei Shi; project administration, Xiang Gao and Jianwei Shi. All authors have read and agreed to the
212 published version of the manuscript.

213 **Funding**

214 The study design was supported by the Shanghai Excellent Young Talents Project in Health System
215 (71774116; 71603182). Data extraction was financially funded by the National Natural Science Foundation
216 of China (72004032). The analysis and interpretation of the data were guided by statisticians and funded by
217 grants from the Shanghai Public Health Outstanding Young Personnel Training Program (GWV-10.2-

218 XD07). The writing and revision, including language improvement, were sponsored by the Chenzhou science
219 and Technology Bureau Funds (JSYF2017038) and Chenzhou science and Technology Bureau Funds
220 (ZDYF201816), the Special project for clinical research of health industry of Shanghai Municipal Health
221 Commission (20204Y0166), Shanghai Public Health System Construction Three-year Action Plan
222 Outstanding Youth Talent Training Program (GWV-10.2-YQ43) and the Chenzhou science and Technology
223 Bureau Funds (ZDYF2020072).

224 **Disclosure**

225 **Conflict of interest:** The author reports no conflicts of interest in this work.

226 **Ethics statement:** Ethical approval for the research protocol was provided by the Medical Research Ethics
227 Committee of the School of Public Health, Fudan University (IRB#2016-04-0586). Information was de-
228 identified prior to analysis. The guidelines outlined in the Declaration of Helsinki were followed.

229 **Registry and the Registration No. of the study/trial:** N/A.

230 **Informed Consent:** N/A.

231 **Animal Studies:** N/A.

232 **References**

- 233 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer
234 statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
235 countries. *Ca-a Cancer Journal for Clinicians*. 2021;71(3):209-49.
- 236 2. Wang Z, Yin Y, Wang J, Zhu Y, Li X, Zeng X. Standardized Incidence Rate, Risk and Survival
237 Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-
238 Control Study. *Frontiers in Oncology*. 2021;11.
- 239 3. Zheng G, Sundquist K, Sundquist J, Forsti A, Hemminki O, Hemminki K. Bladder and upper
240 urinary tract cancers as first and second primary cancers. *Cancer Reports*. 2021.
- 241 4. Donin N, Filson C, Drakaki A, Tan H-J, Castillo A, Kwan L, et al. Risk of Second Primary
242 Malignancies Among Cancer Survivors in the United States, 1992 Through 2008. *Cancer*.
243 2016;122(19):3075-86.
- 244 5. Beisland C, Talleraas O, Bakke A, Norstein J. Multiple primary malignancies in patients with
245 renal cell carcinoma: a national population-based cohort study. *Bju International*. 2006;97(4):698-702.
- 246 6. Liu Y, Zhang P, Zhang Y, Zheng L, Xu W, Hou D, et al. Clinical characteristics and overall
247 survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.
248 *Scientific Reports*. 2021;11(1).
- 249 7. Koo KC, Yoo H, Kim KH, Park SU, Han KS, Rha KH, et al. Prognostic Impact of Synchronous
250 Second Primary Malignancies on the Overall Survival of Patients with Metastatic Prostate Cancer. *Journal*
251 *of Urology*. 2015;193(4):1239-44.
- 252 8. Deng L, Hardardottir H, Song H, Xiao Z, Jiang C, Wang Q, et al. Mortality of lung cancer as a
253 second primary malignancy: A population-based cohort study. *Cancer Medicine*. 2019;8(6):3269-77.

- 254 9. Khanal A, Lashari BH, Kruthiventi S, Arjyal L, Bista A, Rimal P, et al. The risk of second
255 primary malignancy in patients with stage Ia non-small cell lung cancer: a US population-based study. *Acta*
256 *Oncologica*. 2018;57(2):239-43.
- 257 10. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC
258 Cancer Staging Manual and the Future of TNM. *Annals of Surgical Oncology*. 2010;17(6):1471-4.
- 259 11. Goldfarb M, Rosenberg AS, Li Q, Keegan THM. Impact of Latency Time on Survival for
260 Adolescents and Young Adults With a Second Primary Malignancy. *Cancer*. 2018;124(6):1260-8.
- 261 12. Rashed WM, Saad A, Al-Husseini M, Galal AM, Ismael AM, Al-Tayep AM, et al. Incidence of
262 adrenal gland tumor as a second primary malignancy: SEER-based study. *Endocrine Connections*.
263 2018;7(10):1040-8.
- 264 13. Joung JY, Kwon W-A, Lim J, Oh C-M, Jung K-W, Kim SH, et al. Second Primary Cancer Risk
265 among Kidney Cancer Patients in Korea: A Population-Based Cohort Study. *Cancer Research and*
266 *Treatment*. 2018;50(1):293-301.
- 267 14. Khanal A, Budhathoki N, Singh VP, Shah BK. Second Primary Malignancy in Bladder Carcinoma
268 - A Population-based Study. *Anticancer Research*. 2017;37(4):2033-6.
- 269 15. Dawson C, Whitfield H. ABC of urology - Urological malignancy .1. Prostate cancer. *British*
270 *Medical Journal*. 1996;312(7037):1032-4.
- 271 16. Salminen E, Pukkala E, Teppo L. BLADDER-CANCER AND THE RISK OF SMOKING-
272 RELATED CANCERS DURING FOLLOW-UP. *Journal of Urology*. 1994;152(5):1420-3.
- 273 17. Kotake T, Kiyohara H. MULTIPLE PRIMARY CANCERS (MPC) ASSOCIATED WITH
274 BLADDER-CANCER - AN ANALYSIS OF THE CLINICAL AND AUTOPSY CASES IN JAPAN.
275 *Japanese Journal of Clinical Oncology*. 1985;15:201-10.
- 276 18. Kinoshita Y, Singh A, Rovito PM, Jr., Wang CY, Haas GP. Double primary cancers of the
277 prostate and bladder: a literature review. *Clinical prostate cancer*. 2004;3(2):83-6.
- 278 19. Cao W, Chen H-D, Yu Y-W, Li N, Chen W-Q. Changing profiles of cancer burden worldwide and
279 in China: a secondary analysis of the global cancer statistics 2020. *Chinese Medical Journal*.
280 2021;134(7):783-91.
- 281 20. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, et al. Cancer statistics
282 for the year 2020: An overview. *International Journal of Cancer*. 2021;149(4):778-89.
- 283 21. Canadian Cancer Statistics: A 2020 special report on lung cancer. *Health Promotion and Chronic*
284 *Disease Prevention in Canada-Research Policy and Practice*. 2020;40(10):325-.
- 285 22. Feng R-M, Zong Y-N, Cao S-M, Xu R-H. Current cancer situation in China: good or bad news
286 from the 2018 Global Cancer Statistics? *Cancer Communications*. 2019;39.


287
288

Figure legend:

289 **Figure 1.** Data source of the included and analysed SPM patients

290 **Figure 2.** Distribution of MNUT and SPM among all patients.

291 **Figure 3.** Kaplan-Meier analysis of the survival status and risk factors of the patients.



medRxiv preprint doi: <https://doi.org/10.1101/2022.03.10.22272195>; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1. Data source of the included and analysed SPM patients




Figure 2. Distribution of MNUT and SPM among all patients.

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.10.22272495>; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 3. Kaplan-Meier analysis of the survival status and risk factors of the patients.

Note: A indicates the cancer-specific survival of the patients, and B indicates the overall survival of the patients.